Extended Stay America Announces Extension of Paired Share Repurchase Authorization
Jan 02, 2018 21:05 pm UTC| Business
CHARLOTTE, N.C., Jan. 02, 2018 -- Extended Stay America, Inc. and ESH Hospitality, Inc. (NYSE:STAY) (together, the “Company”) today announced that the Company’s Boards of Directors extended the maturity of the combined...
Sabra Health Care REIT, Inc. Completes the Sale of 20 Facilities Leased to Genesis
Jan 02, 2018 21:05 pm UTC| Business
IRVINE, Calif., Jan. 02, 2018 -- Sabra Health Care REIT, Inc. (Nasdaq:SBRA) (Nasdaq:SBRAP) announced today that on December 22, 2017, it completed the previously announced sale of 20 facilities leased to Genesis...
Envigo to Present at the 36th Annual JPMorgan Conference
Jan 02, 2018 21:05 pm UTC| Business
EAST MILLSTONE, N.J., Jan. 02, 2018 -- Envigo, a leading provider of nonclinical contract research services and research models, today announced that Adrian Hardy, Chief Executive Officer, and Patricia Henahan, Chief...
The New Ireland Fund, Inc. Monthly Portfolio Update
Jan 02, 2018 21:05 pm UTC| Business
BOSTON, Jan. 02, 2018 -- The New Ireland Fund, Inc. (NYSE:IRL) today released an updated Monthly portfolio statement as of December 29, 2017. Issuer NameShareholdingUS $ Market Value% of Total AssetsALLIED IRISH...
Jan 02, 2018 21:05 pm UTC| Business
SOUTH SAN FRANCISCO, Calif., Jan. 02, 2018 -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, today announced that on...
LPL Financial Announces Fourth Quarter and Full Year 2017 Earnings Release Date and Conference Call
Jan 02, 2018 21:05 pm UTC| Business
SAN DIEGO, Jan. 02, 2018 -- Leading retail investment advisory firm and independent broker/dealer LPL Financial LLC, a wholly owned subsidiary of LPL Financial Holdings Inc. (NASDAQ:LPLA) (collectively, the “Company”),...
Update on progress in cystic fibrosis programs
Jan 02, 2018 21:02 pm UTC| Business
Positive results with FLAMINGO study C1 corrector GLPG2222 as monotherapy in homozygous Class II F508del CF patients Study over-recruited within 5 months in the US and Europe GLPG2222 was well tolerated when dosed...